Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Conditions: COVID-19; Outcome, Fatal; Tocilizumab; Interleukin 6; Critically Ill Interventions: Drug: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T) Sponsors: University of Ulm Completed

https://clinicaltrials.gov/study/NCT06233357

Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials

More News: Actemra | COVID-19 | Research